Review
Medicine, Research & Experimental
Jose Tuells, Andres F. Henao-Martinez, Carlos Franco-Paredes
Summary: Despite the availability of a vaccine, yellow fever remains a significant preventable disease in endemic regions. Yellow fever is a viral hemorrhagic fever that has had a major impact on human societies. Throughout history, it has caused epidemics and played a role in shaping modern societies. Efforts of scientists have led to the discovery of the virus and the development of a vaccine. In the present day, it is important to enhance immunization activities, ensure fair distribution of vaccines, immunize at-risk populations during outbreaks, and promote vaccination among international travelers.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Review
Immunology
Jolynne Mokaya, Derick Kimathi, Teresa Lambe, George M. Warimwe
Summary: Yellow fever remains a global health threat, with efforts to eliminate it by vaccinating one billion people at risk by 2026. The current vaccine provides good protection, but production challenges limit its use, leading to exploration of alternative dosing strategies. Understanding immune responses to vaccination and exploring antibody characteristics and cell-mediated immunity are important for developing a comprehensive understanding of protective immunity.
Article
Biochemistry & Molecular Biology
Stephane Fraga de Oliveira Tosta, Mariana Santana Passos, Rodrigo Kato, Alvaro Salgado, Joilson Xavier, Arun Kumar Jaiswal, Siomar C. Soares, Vasco Azevedo, Marta Giovanetti, Sandeep Tiwari, Luiz Carlos Junior Alcantara
Summary: Yellow fever is a re-emerging major health issue causing recent outbreaks with high mortality rates, mainly affecting tropical countries in Africa and South America. The development of a multi-epitope vaccine for Yellow fever virus using immunoinformatics approaches shows potential in stimulating both humoral and cellular immune responses, making it a candidate for further experimental validation.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2021)
Article
Immunology
J. Xiang, Q. Chang, J. H. McLinden, N. Bhattarai, J. L. Welch, T. M. Kaufman, Jack T. Stapleton
Summary: Live attenuated vaccines such as the yellow fever virus vaccine can modulate immune functions, but they may also have off-target effects on T-cell receptor signaling, which could impact clinical outcomes.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Biotechnology & Applied Microbiology
Gerardo Montalvo Zurbia-Flores, Christine S. Rollier, Arturo Reyes-Sandoval
Summary: Despite the effectiveness of the yellow fever vaccine, issues such as contraindications and inadequate supply have led to the search for novel vaccine candidates to better control the disease.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Medicine, General & Internal
Ji Ma, Michael Bright Yakass, Sander Jansen, Bert Malengier-Devlies, Dominique Van Looveren, Lorena Sanchez-Felipe, Thomas Vercruysse, Birgit Weynand, Mahadesh Prasad Arkalagud Javarappa, Osbourne Quaye, Patrick Matthys, Tania Roskams, Johan Neyts, Hendrik Jan Thibaut, Kai Dallmeier
Summary: This study demonstrates that the YF-S0 vaccine can induce strong humoral and cellular immunity against yellow fever virus (YFV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters, providing full protection against YFV infection and SARS-CoV-2 strain B1.1.7 (Alpha variant) infection. Importantly, strong pre-existing immunity against the YF17D vector does not interfere with the efficacy of YF-S0 vaccination.
Review
Public, Environmental & Occupational Health
Roshina Gnanadurai, Ines Campos-Matos, Sanch Kanagarajah, Katie Geary, Hilary Simons, Dipti Patel
Summary: This study evaluated the number and type of yellow fever (YF) vaccine incidents in England, Wales and Northern Ireland (EWNI) and found that most incidents were due to incorrect timing or other errors. However, vaccination in contraindicated individuals resulted in one death. These findings helped improve the work and staff training in vaccination centers.
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2022)
Article
Immunology
Flora de Andrade Gandolfi, Cassia Fernanda Estofolete, Marcia Catelan Wakai, Andreia Francesli Negri, Michela Dias Barcelos, Nikos Vasilakis, Mauricio Lacerda Nogueira
Summary: The disease burden of yellow fever virus infection is high in areas with low vaccination coverage. Vaccination is the most effective control strategy for yellow fever, with the licensed vaccines being safe and effective. However, rare cases of neurotropic disease have been observed following vaccination. This report emphasizes the importance of healthcare professionals being aware of and managing such events promptly.
Article
Immunology
Sakiko Shimizu, Ryo Tanaka, Eriko Itoh, Minami Maekawa-Matsuura, Yoichiro Iwase
Summary: Under the pandemic situation, there is a need for sufficient prophylactic vaccines. Intradermal (ID) vaccination is an effective method, but currently not widely used due to technical difficulties. This study presents the design and performance testing results of the ImmuciseTM Intradermal Injection System. The study shows that ImmuciseTM can inject drugs precisely into the ID tissues and is safe to use. An analysis comparing ID administration with standard subcutaneous (SC) administration of influenza vaccine shows that ID administration is equally or more effective up to 180 days later. These findings suggest that ImmuciseTM is an efficient device for distributing a small amount of vaccine widely during a pandemic.
Review
Chemistry, Medicinal
Clairissa A. Hansen, Alan D. T. Barrett
Summary: Yellow fever is a disease prevented by the 17D vaccine, but remains a major public health burden due to supply and demand issues. The World Health Organization has initiated the Eliminate Yellow Fever Epidemics (EYE) initiative, and second-generation vaccine candidates must demonstrate their safety and immunogenicity.
Article
Immunology
Riccardo De Santis, Giovanni Faggioni, Alessandra Amoroso, Andrea Ciammaruconi, Alice Pomponi, Maria Stella Lia, Donatella Amatore, Filippo Molinari, Giancarlo Petralito, Paola Stefanelli, Giovanni Rezza, Florigio Lista
Summary: According to the World Health Organization, one dose of yellow fever vaccine can provide lifelong protection in healthy adults. However, there is limited information available regarding the long-term persistence of neutralizing antibodies. Our study evaluated the persistence of neutralizing antibodies in a large group of military personnel who were vaccinated up to 47 years ago. The results showed that 99.1% of the participants had detectable neutralizing antibodies, with the highest levels observed in those vaccinated within 1 year. These findings confirm that neutralizing antibodies can persist for up to 47 years after a single dose of yellow fever vaccine.
Article
Microbiology
Michael P. Doyle, Joseph R. Genualdi, Adam L. Bailey, Nurgun Kose, Christopher Gainza, Jessica Rodriguez, Kristen M. Reeder, Christopher A. Nelson, Prashant N. Jethva, Rachel E. Sutton, Robin G. Bombardi, Michael L. Gross, Justin G. Julander, Daved H. Fremont, Michael S. Diamond, James E. Crowe
Summary: Yellow fever virus (YFV) is a mosquito-borne virus that occasionally causes outbreaks of severe infection in South America and sub-Saharan Africa. Effective vaccines have been developed, but recent production and distribution issues have left many people vulnerable. This study aimed to isolate an antibody from individuals who had received the YFV vaccine for future use as a biologic drug. The most powerful antiviral antibody was found to be effective in animal models of human infection. These studies provide insights into the human immune response to YFV and offer a potential therapeutic antibody candidate for inhibiting highly virulent strains of the virus.
Review
Public, Environmental & Occupational Health
Leticia Wigg de Araujo Lagos, Ariane de Jesus Lopes de Abreu, Rosangela Caetano, Jose Ueleres Braga
Summary: This study conducted a systematic review and meta-analysis to assess the risk of adverse events after yellow fever vaccination in immunocompromised individuals. The results showed that there was no increased risk of adverse events following vaccination in immunocompromised individuals, regardless of the cause of immunosuppression.
JOURNAL OF TRAVEL MEDICINE
(2023)
Article
Immunology
Ana Carolina dos Reis Albuquerque Cajaraville, Mariana Pierre de Barros Gomes, Tamiris Azamor, Renata Carvalho Pereira, Patricia Cristina da Costa Neves, Paula Mello De Luca, Sheila Maria Barbosa de Lima, Luciane Pinto Gaspar, Elena Caride, Marcos da Silva Freire, Marco Alberto Medeiros
Summary: The attenuated yellow fever (YF) vaccine is highly effective but can cause rare fatal adverse events and has contraindications. Therefore, developing a non-live vaccine is important.
Article
Immunology
Fabienne Piras-Douce, Karine Broudic, Emilie Chautard, Franck Raynal, Virginie Courtois, Sylviane Gautheron, Nathalie Mantel
Summary: The increased demand for yellow fever vaccines has led to global shortages. A new live-attenuated vaccine candidate called vYF, cloned from YF-17D vaccine substrain adapted for growth in Vero cells, showed safety and immunogenicity in cynomolgus macaques. vYF provided effective protection against wild-type YFV Asibi, similar to the currently marketed YF-17D vaccines.
Article
Multidisciplinary Sciences
Remko Schats, Else M. Bijker, Geert-Jan van Gemert, Wouter Graumans, Marga van de Vegte-Bolmer, Lisette van Lieshout, Marielle C. Haks, Cornelus C. Hermsen, Anja Scholzen, Leo G. Visser, Robert W. Sauerwein
Editorial Material
Public, Environmental & Occupational Health
Janneke A. Cox, Leo G. Visser
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2015)
Editorial Material
Public, Environmental & Occupational Health
Patricia Schlagenhauf, Christoph Hatz, Ron Behrens, Leo Visser, Maia Funk, Benedikt Holzer, Catherine Bourquin, Bernhard Beck, Hermann Etter, Hansjakob Furrer, Blaise Genton, Pierre Landry, Francois Chappuis, Louis Loutan, Ulrich Stoessel, Eva Jeschko, Andrea Rossanese, Hans Dieter Nothdurft
TRAVEL MEDICINE AND INFECTIOUS DISEASE
(2015)
Letter
Immunology
David J. van Westerloo, Gijs W. Landman, Roger Prichard, Anne Lespine, Leo G. Visser
CLINICAL INFECTIOUS DISEASES
(2014)
Article
Immunology
Douglas H. Esposito, August Stich, Loic Epelboin, Denis Malvy, Pauline V. Han, Emmanuel Bottieau, Alexandre da Silva, Philipp Zanger, Guenther Slesak, Perry J. J. van Genderen, Benjamin M. Rosenthal, Jakob P. Cramer, Leo G. Visser, Jose Munoz, Clifton P. Drew, Cynthia S. Goldsmith, Florian Steiner, Noemie Wagner, Martin P. Grobusch, D. Adam Plier, Dennis Tappe, Mark J. Sotir, Clive Brown, Gary W. Brunette, Ronald Fayer, Frank von Sonnenburg, Andreas Neumayr, Phyllis E. Kozarsky
CLINICAL INFECTIOUS DISEASES
(2014)
Article
Multidisciplinary Sciences
Else M. Bijker, Remko Schats, Joshua M. Obiero, Marije C. Behet, Geert-Jan van Gemert, Marga van de Vegte-Bolmer, Wouter Graumans, Lisette van Lieshout, Guido J. H. Bastiaens, Karina Teelen, Cornelus C. Hermsen, Anja Scholzen, Leo G. Visser, Robert W. Sauerwein
Article
Computer Science, Information Systems
H. Scheper, R. Derogee, R. Mandad, R. J. P. van der Wal, R. G. H. H. Nelissen, L. G. Visser, M. G. J. de Boer
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
(2019)
Article
Immunology
Emile F. F. Jonker, Marjolein A. C. Uijlings, Leonardus G. Visser, Darius Soonawala
Article
Health Care Sciences & Services
Lemmy Schakel, Dieuwke S. Veldhuijzen, Henriet van Middendorp, Corine Prins, Anne M. H. F. Drittij, Frank Vrieling, Leo G. Visser, Tom H. M. Ottenhoff, Simone A. Joosten, Andrea W. M. Evers
JOURNAL OF MEDICAL INTERNET RESEARCH
(2020)
Article
Public, Environmental & Occupational Health
Mareen D. Rosenstein, Adriette W. de Visser, Leo G. Visser, Anna H. E. Roukens
Summary: Research shows that older travelers aged 60 and over remain seropositive 10 years after primary yellow fever vaccination, suggesting that a single dose of the vaccine can provide long-lasting immunity for at least a decade.
JOURNAL OF TRAVEL MEDICINE
(2021)
Review
Immunology
H. Scheper, L. M. Gerritsen, B. G. Pijls, S. A. Van Asten, L. G. Visser, M. G. J. De Boer
Summary: The use of rifampicin in the treatment of staphylococcal prosthetic joint infections may only prevent a small fraction of treatment failures, with varying success rates for different strains of Staphylococcus in PJI.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Virology
Alhena Reyes, Ellen C. Carbo, Johan S. van Harinxma Thoe Slooten, Margriet E. M. Kraakman, Igor A. Sidorov, Eric C. J. Claas, Aloys C. M. Kroes, Leo G. Visser, Jutte J. C. Vries De
Summary: Viral metagenomics can help detect viral pathogens and co-infections in international travellers with febrile illness, and the use of probes for enrichment results in high genome coverage and depth.
JOURNAL OF CLINICAL VIROLOGY
(2021)
Article
Virology
Manon L. M. Prins, Corine Prins, Jutte J. C. de Vries, Leo G. Visser, Anna H. E. Roukens
Summary: This study investigated the safety and immunogenicity of nanoporous microneedle arrays (npMNA) for delivering the mRNA-1273 vaccine. The results showed that the antibody and T cell responses were not induced by the npMNA delivery of the vaccine. Further research and improvements are needed for the use of npMNA.
Review
Immunology
Manu P. Bilsen, Rosa M. H. Jongeneel, Caroline Schneeberger, Tamara N. Platteel, Cees van Nieuwkoop, Lona Mody, Jeffrey M. Caterino, Suzanne E. Geerlings, Bela Koves, Florian Wagenlehner, Simon P. Conroy, Leo G. Visser, Merel M. C. Lambregts
Summary: Urinary tract infection (UTI) definitions in current research studies are highly varied in terms of clinical signs and diagnostic tests. Most studies do not meet the criteria outlined in existing research guidelines. This systematic review highlights the need for a consensus-based, research reference standard for defining UTI.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Public, Environmental & Occupational Health
E. G. J. von Asmuth, H. J. Brockhoff, J. Wallinga, L. G. Visser
JOURNAL OF TRAVEL MEDICINE
(2019)